GNI Group Ltd. · TSE:2160
GNI — Q3 2026 Earnings Presentation
44 slides from GNI's earnings presentation, Nov 13, 2026
Slide 1: Q3 FY2026 Financial Results Presentation
GNI Group Ltd. Q3 FY2026 Financial Results Presentation We Bring New Hope to Life November 13, 2026 Securities Code: TSE:2160
Slide 2: Disclaimer
We Bring New Hope to Life Disclaimer [Cautionary Statement Regarding Forward-Looking Statements] Statements in this material (including the main text of the press release and all supplementary materials) concerning the Group’s future business development, global expansion of its new drug pipeline, c
Slide 3: Agenda
We Bring New Hope to Life Agenda 1. Company Overview 2. Q3 FY2026 Consolidated Financial Highlights 3. Q3 FY2026 Business Updates 4. Appendix © 2026 GNI Group Ltd. All rights reserved 3
Slide 4: 1. Company Overview
We Bring New Hope to Life 1. Company Overview © 2026 GNI Group Ltd. All rights reserved 4
Slide 5: Establishing Japan as a Revenue Pillar Alongside the U.S. and China
We Bring New Hope to Life Establishing Japan as a Revenue Pillar Alongside the U.S. and China Aiming to Become a Global BioPharma, with Japan Business Profitability as the Next Growth Driver Achieving Profitability in Japan Through the Regional Profit Outlook Consolidation of Ayumi Pharmaceutical Pr
Slide 6: Launchpad for an Emerging Global Biopharma
We Bring New Hope to Life Launchpad for an Emerging Global Biopharma Acquired ZooLabo and Ayumi Pharmaceuticals, Merged GYRE and Cullgen, Rebuilding Medtech GNI Group Group Company (2160.T) Gyre Therapeutics Ayumi Pharmaceuticals Medtech Group Global drug discovery and development Springboard to or
Slide 7: Growth Trend Built around Three Core Businesses
We Bring New Hope to Life Growth Trend Built around Three Core Businesses Building a Foundation across Pharma, Biotech, and Medtech toward Becoming a Global Biopharma Assuming Full-Year Consolidation of AYUMI Pharmaceutical Revenue Operating Profit/ Loss (Millions of yen) 68,482 Consolidated from Q3
Slide 8: GNI Group's Growth Vision
We Bring New Hope to Life GNI Group’s Growth Vision Aim to achieve our medium- to long-term growth vision through the continued execution of multiple growth strategies* Drug Value F351 Launch New Products from Ayumi Launch of Multiple Potential Sales of Medical Aesthetics Products Blockbuster Drugs*
Slide 9: Pipeline
We Bring New Hope to Life Pipeline *The development details and schedule may change depending on future progress and other factors. In addition, the Ayumi Pharmaceutical product pipeline shown in the table below presents selected major products and does not cover all products. Product Modality| Targ
Slide 10: 2. Q3 FY2026 Consolidated Financial Highlights
We Bring New Hope to Life 2. Q3 FY2026 Consolidated Financial Highlights © 2026 GNI Group Ltd. All rights reserved 10
Slide 11: Q3 FY2026 Financial Highlights
We Bring New Hope to Life Q3 FY2026 Financial Highlights A new phase of growth toward becoming a global biopharma company, driven by the consolidation of Ayumi Pharmaceuticals and progress on F351’s NDA • Revenue up 53.6% YoY, reflecting the consolidation of three months of Ayumi Pharmaceuticals’ re
Slide 12: Consolidated Income Statement (Q3 YTD: January–September)
We Bring New Hope to Life Consolidated Income Statement (Q3 YTD: January–September) Revenue increased significantly, reflecting three months (July–September) of Ayumi Pharmaceutical's results. Approximately JPY 2.5 billion in acquisition-related expenses (including interest) was recognized in Q3. Se
Slide 13: Segment Performance (Q3 YTD: January–September)
We Bring New Hope to Life Segment Performance (Q3 YTD: January–September) Steady performance in the existing pharmaceutical business, with YoY revenue growth excluding Ayumi. FY2025 FY2026 FY2026 FY2021 FY2022 FY2023 FY2024 FY2025 Inc. / (Dec.) Factors for increase/decrease Millions of yen Q3 Q3 Fo
Slide 14: Other Segment
We Bring New Hope to Life Other Segment The Other segment consists of 14 companies, including GNI Group (the Company), which holds global headquarters functions, and Gyre Therapeutics, a Nasdaq-listed company that conducts research and development in the United States, as well as other entities maki
Slide 15: Consolidated Balance Sheet
We Bring New Hope to Life Consolidated Balance Sheet Total assets increased to approximately 2.5 times the previous fiscal year-end level following the consolidation of Ayumi. PPA remains provisional. Millions of yen FY2024 Q4 FY2025 Q4 FY2026 Q3 Inc. / (Dec.) Total non-current Assets 42,720 43,057
Slide 16: 連結貸借対照表
We Bring New Hope to Life 連結貸借対照表 あゆみ製薬の連結により、総資産は前期末の約2.5倍に拡大。PPA(取得原価配分)は現時点で暫定処理 FY2024 FY2025 FY2026 前期比増減 (単位:百万円) Q4 Q4 Q3 非流動資産合計 42,720 43,057 141,167 98,110 のれん 15,994 16,648 63,339 46,691 • あゆみ製薬のれんを計上(PPA暫定) • あゆみ製薬連結による増加(販売権及び資産計上開発費) 無形資産 11,026 12,347 56,631 44,284 • F351のNDA申請費用及びPha
Slide 17: Consolidated Balance Sheet / Goodwill and Intangible Assets
We Bring New Hope to Life Consolidated Balance Sheet / Goodwill and Intangible Assets Increase of approximately JPY 90 billion in goodwill and intangible assets due to the acquisition of Ayumi Pharmaceuticals. JPY Amounts (millions of yen) Foreign Currency (Local Currency Basis) Breakdown FY2024 Q4
Slide 18: Consolidated Balance Sheet: Expansion Following the Acquisition of Ayumi
We Bring New Hope to Life Consolidated Balance Sheet: Expansion Following the Acquisition of Ayumi Strengthened the capital base in connection with the acquisition of Ayumi Pharmaceutical Changes in the Consolidated Balance Sheet* Millions of yen Capital Structure Goodwill Non-current • Total assets
Slide 19: R&D expense
We Bring New Hope to Life R&D expense • YoY increase in R&D expenses driven by progress in Gyre’s preparations to initiate TPD trials next fiscal year and advance F351 development in the U.S. • Increase in capitalized development costs reflecting Gyre Pharmaceuticals’ NDA filing costs ahead of the n
Slide 20: FY2026 Consolidated Earnings Forecast
We Bring New Hope to Life FY2026 Consolidated Earnings Forecast Consolidated Results: Earnings Forecast Unchanged FY2024 Actual FY2025 Actual FY2026 Forecast Millions of Yen Consolidated Revenue 23,611 26,840 47,327 1 Pharma 15,847 17,314 40,622 Biotech 1,439 789 177 Medtech 5,189 7,584 5,647 Others
Slide 21: 3. Q3 FY2026 Business Updates
We Bring New Hope to Life 3. Q3 FY2026 Business Updates © 2026 GNI Group Ltd. All rights reserved 21
Slide 22: Pharma
We Bring New Hope to Life Pharma Ayumi Pharmaceuticals’ revenue up 16% YoY, driven by higher sales of existing products and contributions from the osteoporosis product it began selling in July 2026. Pharma Business Revenue Trends (JPY million) Ayumi Pharmaceuticals’ Revenue Mix (July–September) Only
Slide 23: Accelerating Ayumi Pharmaceuticals' Growth Strategy through Group Synergies
We Bring New Hope to Life Accelerating Ayumi Pharmaceuticals’ Growth Strategy through Group Synergies Proactive expansion beyond pain management and rheumatology into new therapeutic areas, accelerating growth as the GNI Group’s business platform in Japan. Revenue growth outlook Revenue growth outlo
Slide 24: Strengthening Ayumi Pharmaceuticals' Production Capacity
We Bring New Hope to Life Strengthening Ayumi Pharmaceuticals’ Production Capacity Planned expansion of production capacity to meet the need for stable supply in Japan. Current Manufacturing Operations Tamagawa Factory/ Atsugi Plant Main Manufacturing Site for Calonal Tablets (Antipyretic and Analge
Slide 25: Strong Sales Capabilities across Hospitals and Clinics in Japan
We Bring New Hope to Life Strong Sales Capabilities across Hospitals and Clinics in Japan Building strong relationships of trust with medical institutions through a comprehensive product portfolio AYUMI’s Broad Portfolio Covering a Wide Range of Antirheumatic Therapies Extensive Sales Network across
Slide 26: Process Toward F351 Launch
We Bring New Hope to Life Process Toward F351 Launch Received formal acceptance notification for the New Drug Application (NDA) on May 13, 2026. Currently under review with Priority Review designation. Launch expected in H1 2027, subject to NDA approval. Description Progress 1. Pre-NDA Meeting Prior
Slide 27: Major Commercial Products and Drug Candidates
We Bring New Hope to Life Major Commercial Products and Drug Candidates Commercial Products Product Candidates ETUARYTM F351 (Generic name:Pirfenidone) Chinese:艾思瑞® (Generic name:Hydronidone) • Treatment for idiopathic pulmonary fibrosis (IPF) • A potential blockbuster drug candidate for liver fibro
Slide 28: Major TPD Drug Candidates
We Bring New Hope to Life Major TPD Drug Candidates Aiming to create new drugs by leveraging its proprietary TPD platform, uSMITE CG001419 Cancer-induced bone pain CG009301 Acute Myeloid Leukemia / AML • Potential to become a first-in-class oral pan-TRK protein degrader for pain treatment • GSPT1 re
Slide 29: Protein Degraders: Degrading Disease-Causing Proteins Rather than Inhibiting Them
We Bring New Hope to Life Protein Degraders: Degrading Disease-Causing Proteins Rather than Inhibiting Them Generating multiple new drug candidates for cancer, autoimmune diseases, and pain from a single platform Disease- Ub causing Ubiquitin Chain Ub protein Ub Ub Ub RING E2 Degrader Lys Lys Protea
Slide 30: Three Key Degrader Candidates: Advancing into Clinical Development in 2027
We Bring New Hope to Life Three Key Degrader Candidates: Advancing into Clinical Development in 2027 Drug-resistant cancer, autoimmune diseases, and cancer pain are all areas of high unmet medical need that existing drugs do not adequately address. CG923308 CG620953 CG001419 CDK2/Cyclin E Dual Degra
Slide 31: DAC: A Next-Generation ADC Combining Protein Degraders with Antibody Conjugates
We Bring New Hope to Life DAC: A Next-Generation ADC Combining Protein Degraders with Antibody Conjugates Two layers of selectivity: targeting cancer cells with antibodies and eliminating disease-causing proteins with protein degraders Gyre’s DAC Platform Targeting Diverse Cancer Types Two Layers of
Slide 32: Medtech
We Bring New Hope to Life Medtech Optimizing Resources across the Company for the Second Founding Phase: A Strategic Shift from “Quantity” to “Quality” Medtech Group Performance Trends Revenue quadrupled over the past five years, while the operating profit margin declined from 47% to 17%. Factors Be
Slide 33: Medtech
We Bring New Hope to Life Medtech Optimizing Resources across the Company for the Second Founding Phase: A Strategic Shift from “Quantity” to “Quality” Profitability Recovery Expansion into Medical Aesthetics Medtech Group Listing Restoring Profitability in Acquisition of OsDerma’s Potential Listing
Slide 34: Expansion into the Medical Aesthetics Market through OsDerma
We Bring New Hope to Life 【Medtech】Expansion into the Medical Aesthetics Market through OsDerma DermiraCa® Developed by OsDerma Aiming to Expand Market Share and Establish a Strong Competitive Advantages Tighter Regulation of Off-Label Use in Medical Aesthetics Expected to Provide a Tailwind Brand i
Slide 35: 4. Appendix: F351
We Bring New Hope to Life 4. Appendix: F351 © 2026 GNI Group Ltd. All rights reserved 35
Slide 36: Hepatitis is the second most common cause of death from infectious disease
We Bring New Hope to Life F351: Bring New Hope to Life, Powering a Brighter Future for CHB Patients. Hepatitis is the second most common cause of death from infectious disease in the world World Hepatitis Summit 9 April 2024 WHO: Global hepatitis report 2024 (p244) Estimated deaths from viral hepati
Slide 37: An estimated 60-79.7 million people in China are infected with hepatitis B virus
We Bring New Hope to Life F351: Bring New Hope to Life, Powering a Brighter Future for CHB Patients. An estimated 60-79.7 million people# in China are infected with hepatitis B virus Stage Description Infection with the hepatitis B virus. If the acute hepatitis does not resolve and becomes chronic,
Slide 38: Estimated Peak Patient Population for F351
We Bring New Hope to Life F351: Bring New Hope to Life, Powering a Brighter Future for CHB Patients. Estimated Peak Patient Population for F351: approximately 3.0 to 7.5 million# (based on GNI’s own view) 1. Number of Hepatitis B Patients Terms Number of people proportion Survey results: published i
Slide 39: Estimated total number of patients treated by the top three products
We Bring New Hope to Life Estimated total number of patients treated by the “top three” products Recommended in China’s National Estimated Retail Product Name Key Manufacturer Estimated Wholesale Value Market Share Market Positioning & Share Status Clinical Guidelines / Annual Cost Raw Materials Val
Slide 40: Estimated total number of patients treated by the top three products
We Bring New Hope to Life Estimated total number of patients treated by the “top three” products Based on market data, it is estimated that approximately 0.4–0.6 million patients in China are effectively receiving treatment annually with three major traditional Chinese medicines. Given an estimated
Slide 41: F351 is expected to drive demand and establish a new market
We Bring New Hope to Life F351 is expected to drive demand and establish a new market Historically, in Western medicine, the treatment of chronic hepatitis B Traditional Chinese medicines primarily contribute through anti-fibrotic effects and immune modulation. has been limited to "delaying" disease
Slide 42: Number of Patients on Antiviral Therapy for Hepatitis B in China
We Bring New Hope to Life Number of Patients on Antiviral Therapy for Hepatitis B in China According to studies by the China Center for Disease Control and Prevention (CDC) and the WHO-affiliated Polaris Observatory, it is estimated that approximately 5–6 million patients in China are receiving anti
Slide 43: Toward a Second Founding Phase: Main Group Structure
We Bring New Hope to Life Toward a Second Founding Phase: Main Group Structure GNI Group Ltd. TSE:2160 Pharma/ Drug discovery Medical Devices Other (Biomaterials) 100% 100% 70% 100% Berkeley Advanced Shanghai Genomics Gyre Therapeutics Biomaterials (Nasdaq: GYRE) Ayumi Pharmaceutical Holdings Biomat
Slide 44: Contact Info: GNI Group Ltd. Investor Relations
We Bring New Hope to Life Contact Info: GNI Group Ltd. Investor Relations : IR@gnipharma.com : www.gnipharma.com 44